Business
BioRestorative Therapies Announces Notice of Allowance on Key Patent for its BRTX-100® Disc Program
Notice of Allowance Grants Protection for BioRestorative’s Phase 2 Clinical Program to Treat Chronic Lumbar Disc Disease MELVILLE, N.Y., Feb. 16, 2022 (GLOBE
About this update from Biorestorative Therapies, Inc.
[{"type":"text","content":"Notice of Allowance Grants Protection for BioRestorative’s Phase 2 Clinical Program to Treat Chronic Lumbar Disc Disease MELVILLE, N.Y., Feb. 16, 2022 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc. (the “Company” or “BioRestorative”) (NASDAQ: BRTX), a clinical stage company focused on stem cell-based therapies, today announced that the United States Patent and Trademark Office has issued a notice of allowance for a patent application related to the Company’s BRTX-100® core clinical program. Claims granted under the key patent cover a method of preparing BRTX-100®, a stem cell population derived from bone marrow, grown under hypoxic (low oxygen) conditions, and used to treat avascular zones, such as the intervertebral disc. The method of preparing stem cells under low oxygen conditions is designed to optimize the therapeutic potential of the cells once implanted in the low oxygen environment of the damaged disc. “The issuance of this key patent is among the most significant milestones for the Company as the protection granted in the claims covers methodologies used in the manufacturing of our cell-based therapeutic,\" said Lance Alstodt, the Company’s CEO. \"We intend to continue expanding and fortifying our intellectual property portfolio for BRTX-100® in the U.S. and internationally as we advance our clinical development program to treat chronic lumbar disc disease, which we believe presents a significant potential market opportunity. Additionally, we believe this is in line with our promise to continue to build fundamental value to our business and for our shareholders.” About BioRestorative Therapies, Inc. BioRestorative Therapies, Inc. (www.biorestorative.com) develops therapeutic products using cell and tissue protocols, primarily involving adult stem cells. Our two core programs, as described below, relate to the treatment of disc/spine disease and metabolic disorders: • Disc/Spine Program (brtxDISC™): Our lead cell therapy candidate, BRTX-100, is a product formulated from autologous (or a person’s own) cultured mesenchymal stem cells collected from the patient’s bone marrow. We intend that the product will be used for the non-surgical treatment of painful lumbosacral disc disorders or as a complementary therapeutic to a surgical procedure. The BRTX-100 production process utilizes proprietary technology and involves co...